Heidi M. Ott

3.9k total citations
6 papers, 170 citations indexed

About

Heidi M. Ott is a scholar working on Molecular Biology, Hematology and Organic Chemistry. According to data from OpenAlex, Heidi M. Ott has authored 6 papers receiving a total of 170 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 2 papers in Hematology and 1 paper in Organic Chemistry. Recurrent topics in Heidi M. Ott's work include Cancer-related gene regulation (3 papers), Epigenetics and DNA Methylation (3 papers) and RNA modifications and cancer (2 papers). Heidi M. Ott is often cited by papers focused on Cancer-related gene regulation (3 papers), Epigenetics and DNA Methylation (3 papers) and RNA modifications and cancer (2 papers). Heidi M. Ott collaborates with scholars based in United States. Heidi M. Ott's co-authors include Christian A. Baumann, Mark R. Player, Raymond J. Patch, Melissa B. Pappalardi, Ryan G. Kruger, Sharad K. Verma, Caretha L. Creasy, Benjamin Schwartz, Michael T. McCabe and Dashyant Dhanak and has published in prestigious journals such as Cancer Research, Journal of Medicinal Chemistry and Molecular Cancer Therapeutics.

In The Last Decade

Heidi M. Ott

6 papers receiving 164 citations

Peers

Heidi M. Ott

MB

OC

HEMAT

CR

ONCOL

Kenneth J. Stauffer United States

Kerstin A. Effenberger United States

Minna Bui United States

Giuseppe Scozzafava United Kingdom

Chengjun Zhu China

Susan LaGreca United States

John Sapienza Switzerland

Erin P. Keaney Switzerland

Jacob I. Stuckey United States

Hairui Su United States

Kenneth J. Stauffer United States

Heidi M. Ott

77 ×0.7

MB

59 ×0.9

OC

51 ×3.4

HEMAT

6 ×0.4

CR

41 ×3.4

ONCOL

Citations per year, relative to Heidi M. Ott Heidi M. Ott (= 1×) peers Kenneth J. Stauffer

Countries citing papers authored by Heidi M. Ott

Since Specialization

Citations

This map shows the geographic impact of Heidi M. Ott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heidi M. Ott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heidi M. Ott more than expected).

Fields of papers citing papers by Heidi M. Ott

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heidi M. Ott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heidi M. Ott. The network helps show where Heidi M. Ott may publish in the future.

Co-authorship network of co-authors of Heidi M. Ott

This figure shows the co-authorship network connecting the top 25 collaborators of Heidi M. Ott. A scholar is included among the top collaborators of Heidi M. Ott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heidi M. Ott. Heidi M. Ott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Ott, Heidi M., Alan P. Graves, Melissa B. Pappalardi, et al.. (2014). A687V EZH2 Is a Driver of Histone H3 Lysine 27 (H3K27) Hypertrimethylation. Molecular Cancer Therapeutics. 13(12). 3062–3073. 35 indexed citations

2.

Aller, Glenn S. Van, Melissa B. Pappalardi, Heidi M. Ott, et al.. (2013). Long Residence Time Inhibition of EZH2 in Activated Polycomb Repressive Complex 2. ACS Chemical Biology. 9(3). 622–629. 45 indexed citations

3.

Creasy, Caretha L., Michael T. McCabe, Susan Korenchuk, et al.. (2012). Abstract 4700: A novel selective EZH2 inhibitor exhibits anti-tumor activity in lymphoma with EZH2 activating mutations. Cancer Research. 72(8_Supplement). 4700–4700. 2 indexed citations

4.

Gaul, Micheal D., et al.. (2007). 4-Amino-6-piperazin-1-yl-pyrimidine-5-carbaldehyde oximes as potent FLT-3 inhibitors. Bioorganic & Medicinal Chemistry Letters. 17(17). 4861–4865. 15 indexed citations

5.

Patch, Raymond J., Christian A. Baumann, Jian Liu, et al.. (2006). Identification of 2-acylaminothiophene-3-carboxamides as potent inhibitors of FLT3. Bioorganic & Medicinal Chemistry Letters. 16(12). 3282–3286. 25 indexed citations

6.

Chadha, Naresh K., Benjamin Brandt, Davoud Asgari, et al.. (2004). 2-Hydroxy-4,6-diamino-[1,3,5]triazines: A Novel Class of VEGF-R2 (KDR) Tyrosine Kinase Inhibitors. Journal of Medicinal Chemistry. 48(6). 1717–1720. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact